
Seoul International Digestive Disease Symposium 2025



April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea

Frontiers in Digestive Research and Practice



SIDDS 2029

| Name | Won Kim |
|-------------|---|
| Affiliation | Seoul National University College of Medicine, |
| | Seoul Metropolitan Government Boramae Medical Center |
| Country | Republic of Korea |
| Major Field | Integrated multi-omics approach for precision medicine in NAFLD |

Educational Background

1991-1997 Bachelor's degree, Seoul National University College of Medicine 2000-2002 Master's degree, Seoul National University College of Medicine 2005-2007 Doctoral degree, Seoul National University College of Medicine

Professional Experience

2020-now Associate Professor, Seoul National University College of Medicine

2018-2019 Director of Research Committee, Korean Liver Cancer Association

2022-2023 Director of Research and Project Committee, Korean Association for the Study of Liver

2024-now Director of Publication Committee, Korean Association for the Study of Liver

2024-now Editor-in-Chief, Clinical and Molecular Hepatology (IF 8.9)

2023-now President, KASL-Alcohol-Related Problem Study Group

Main Scientific Publications

- 1. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. Journal of Hepatology (2017)
- 2. Activating Transcription Factor 3 Is a target molecule linking hepatic steatosis to impaired glucose homeostasis. Journal of Hepatology (2017)
- 3. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. Journal of Hepatology (2019)
- 4. Overproduction of inter--trypsin inhibitor heavy chain 1 after loss of G13 in liver exacerbates systemic insulin resistance in mice. Science Translational Medicine (2019)
- 5. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD. Nature Communication (2020)
- 6. Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease. Journal of Hepatology (2021)
- 7. A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects wth Nonalcoholic Fatty Liver Disease. Clin. Gastroenterol. Hepatol. (2022)
- 8. Interaction effect between NAFLD severity and high carbohydrate diet on gut microbiome alteration and hepatic de novo lipogenesis. Gut Microbes (2022)
- 9. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin. Gastroenterol. Hepatol. (2023)
- 10. Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease. JAMA Internal Medicine. (2024)